{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:51:03Z","timestamp":1790351463125,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Biostatistics Core Facility at the H. Lee Moffitt Cancer Center & Research Institute, an NCI-designated Comprehensive Cancer Center","award":["P30-CA076292"],"award-info":[{"award-number":["P30-CA076292"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.leukres.2018.10.002","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T03:54:24Z","timestamp":1539057264000},"page":"89-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease"],"prefix":"10.1016","volume":"74","author":[{"given":"Kendra","family":"Sweet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Hazlehurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Sahakian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Nodzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Kayali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Hyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5405","key":"10.1016\/j.leukres.2018.10.002_bib0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.leukres.2018.10.002_bib0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.leukres.2018.10.002_bib0015","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2018.10.002_bib0020","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.23728","article-title":"Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"19","key":"10.1016\/j.leukres.2018.10.002_bib0025","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2018.10.002_bib0030","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2018.10.002_bib0035","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2018.10.002_bib0040","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"July (7)","key":"10.1016\/j.leukres.2018.10.002_bib0045","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.leukres.2018.10.002_bib0050","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.787.787","article-title":"Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the euro-ski trial","volume":"128","author":"Mahon","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2018.10.002_bib0055","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.790.790","article-title":"Discontinuation of nilotinib in patients with chronic myeloid leukemia who have maintained deep molecular responses for at least 2 years: a multicenter phase 2 stop nilotinib (nilst) trial","volume":"128","author":"Kadowaki","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2018.10.002_bib0060","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.791.791","article-title":"Discontinuation of dasatinib after deep molecular response for over 2 years in patients with chronic myelogenous leukemia and the unique profiles of lymphocyte subsets for successful discontinuation: a prospective, multicenter Japanese trial (D-STOP trial)","volume":"128","author":"Kumagai","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.leukres.2018.10.002_bib0065","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.792.792","article-title":"Treatment-free remission in patients with chronic myeloid leukemia in chronic phase according to reasons for switching from imatinib to nilotinib: subgroup analysis from ENESTop","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2018.10.002_bib0070","series-title":"Clinical Practice Guidelines in Oncology Chronic Myeloid Leukemia, (Version 1.2018)","author":"NCCN","year":"2017"},{"issue":"10","key":"10.1016\/j.leukres.2018.10.002_bib0075","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2018.10.002_bib0080","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2018.10.002_bib0085","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2018.10.002_bib0090","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2018.10.002_bib0095","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1158\/1535-7163.MCT-08-0314","article-title":"Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance","volume":"7","author":"Bewry","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.leukres.2018.10.002_bib0100","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.leukres.2011.12.002","article-title":"Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML","volume":"36","author":"Nair","year":"2012","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.leukres.2018.10.002_bib0105","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.leukres.2013.11.006","article-title":"Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia","volume":"38","author":"Quintarelli","year":"2014","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.leukres.2018.10.002_bib0110","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1517\/14712598.2010.484801","article-title":"INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect","volume":"10","author":"Chiappori","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"issue":"10","key":"10.1016\/j.leukres.2018.10.002_bib0115","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","article-title":"Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors","volume":"108","author":"Levis","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2018.10.002_bib0120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1023\/A:1008842517972","article-title":"Measurement of fatigue in cancer patients: development and validation of the fatigue symptom inventory","volume":"7","author":"Hann","year":"1998","journal-title":"Qual. Life Res."},{"issue":"5","key":"10.1016\/j.leukres.2018.10.002_bib0125","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.1998.16.5.1689","article-title":"Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer","volume":"16","author":"Broeckel","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2018.10.002_bib0130","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jpainsymman.2007.11.013","article-title":"Identifying clinically meaningful fatigue with the fatigue symptom inventory","volume":"36","author":"Donovan","year":"2008","journal-title":"J. Pain Symptom Manage."},{"issue":"7","key":"10.1016\/j.leukres.2018.10.002_bib0135","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"issue":"17","key":"10.1016\/j.leukres.2018.10.002_bib0140","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","article-title":"Gimema, health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population","volume":"118","author":"Efficace","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2018.10.002_bib0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199907013410103","article-title":"Long-term survival and late deaths after allogeneic bone marrow transplantation. Late effects working committee of the International bone marrow transplant registry","volume":"341","author":"Socie","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2018.10.002_bib0150","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.leukres.2018.10.002_bib0155","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.18632\/oncotarget.2353","article-title":"Selective JAK2\/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem\/progenitor cells","volume":"5","author":"Lin","year":"2014","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.leukres.2018.10.002_bib0160","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4541.4541","article-title":"Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f\/u) of ENESTnd","volume":"124","author":"Larson","year":"2014","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618302480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618302480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T22:46:32Z","timestamp":1572043592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618302480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":32,"alternative-id":["S0145212618302480"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.10.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}